Teleflex (NYSE:TFX) and Apyx Medical (NASDAQ:APYX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations and dividends.
This table compares Teleflex and Apyx Medical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
91.2% of Teleflex shares are owned by institutional investors. Comparatively, 45.4% of Apyx Medical shares are owned by institutional investors. 2.4% of Teleflex shares are owned by company insiders. Comparatively, 6.0% of Apyx Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Teleflex pays an annual dividend of $1.36 per share and has a dividend yield of 0.4%. Apyx Medical does not pay a dividend. Teleflex pays out 13.7% of its earnings in the form of a dividend.
Earnings & Valuation
This table compares Teleflex and Apyx Medical’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Teleflex||$2.45 billion||6.30||$200.80 million||$9.90||33.75|
|Apyx Medical||$16.69 million||14.71||$64.01 million||($0.29)||-24.97|
Teleflex has higher revenue and earnings than Apyx Medical. Apyx Medical is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent recommendations and price targets for Teleflex and Apyx Medical, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Teleflex presently has a consensus target price of $328.86, suggesting a potential downside of 1.58%. Apyx Medical has a consensus target price of $8.00, suggesting a potential upside of 10.50%. Given Apyx Medical’s higher probable upside, analysts plainly believe Apyx Medical is more favorable than Teleflex.
Volatility and Risk
Teleflex has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, Apyx Medical has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500.
Teleflex beats Apyx Medical on 11 of the 16 factors compared between the two stocks.
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease. The company also provides interventional access products that are used in dialysis, oncology, and critical care therapies; and cardiac care products, such as diagnostic and intra-aortic balloon catheters, and capital equipment. In addition, it offers anesthesia products, such as pain management products for use in surgical and obstetric procedures; airway management products and related devices for use in pre-hospital emergency and hospital settings; and other pre-hospital emergency products. Further, the company offers surgical products, including Weck Ligation Systems, Weck EFx Fascial Closure Systems, Percutaneous Surgical Systems, Weck Vista bladeless access ports, Deknatel sutures, and Pilling and Kmedic surgical instruments; products for use in acute care settings for diagnostic and therapeutic procedures, and in general and specialty surgical applications; and single-use respiratory, urology, and interventional urology products. Additionally, it provides devices and instruments for other medical device manufacturers, such as custom-engineered extrusions, diagnostic and interventional catheters, balloon sheath/dilator sets and kits, sutures, performance fibers, and bioresorbable resins and fibers. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was founded in 1943 and is headquartered in Wayne, Pennsylvania.
About Apyx Medical
Apyx Medical Corporation, a medical technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. It operates through two segments, Advanced Energy and original equipment manufacturing (OEM). The company develops J-Plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue. It markets and sells Helium Plasma Technology under the Renuvion brand name in the cosmetic surgery market and under the J-Plasma brand name in the hospital surgical market. The company's Renuvion cosmetic technology enables plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and the J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminating unintended tissue trauma. It also designs, develops, manufactures, and sells electrosurgical and OEM generators and related accessories for medical device manufacturers. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.